3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
9
Colorectal Neoplasms
5
Breast Neoplasms
5
Neoplasms
4
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Urinary Bladder Neoplasms
2
Stomatitis
2
Rectal Neoplasms
2
Precancerous Conditions
2
Male Urogenital Diseases
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Cardiovascular Diseases
2
Carcinoma, Non-Small-Cell Lung
2
Vascular Diseases
1
Ulcer
1
Thrombocytopenia
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunction, Physiological
1
Radiation-induced Injuries in Patients With Rectal Cancer
1
Radiation Injuries
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Polycystic Ovary Syndrome
1
Ovarian Neoplasms
1
Non-melanoma Skin Cancer
1
Neurotoxicity Syndromes
1
Myocardial Ischemia
1
Interventions
dacetuzumab
2
ficlatuzumab
1
Vorinostat
1
Vitamin E
1
Lenalidomide
1
Erlotinib Hydrochloride
1
Dexamethasone
1
Calcium Dobesilate
1
Bortezomib
1
Blood Specimen Collection
1
Aspirin
1
ARQ531
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Vascular Diseases
×
Vitamin E
×
Clear all
NCT00000479
2012-06-15
WHS
Brigham and Women's Hospital
Phase 3
Completed
39,876 enrolled
11 charts